SCHEMBL676532

SCHEMBL676532

[O]c1ccc2ccccc2c1Oc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
KMT2A Q03164 1/20 0.50
PGR P06401 2/20 0.43
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP2A6 P11509 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LTA4H P09960 1/20 0.41
KDM1A O60341 1/20 0.40
HPRT1 P00492 1/20 0.38
ATM Q13315 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PAX8 Q06710 1/20 0.36
WDR5 P61964 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KCNA3 P22001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8704686 0.85 ENPP3 (0.44) MAPTKDM4EGLAKMT2ATSHR
SCHEMBL6784168 0.82 NPBWR1 (0.49) MAPTKDM4EGLAKMT2APGR
SCHEMBL1052575 0.78 MAPT (0.52) MAPTKDM4EGLAKMT2ATSHR
SCHEMBL5992678 0.77 KDM4E (0.50) MAPTKDM4EGLAKMT2ATSHR
SCHEMBL10627973 0.77 KDM4E (0.46) MAPTKDM4EGLAKMT2AALDH1A1
SCHEMBL1402567 0.76 ALDH1A1 (0.50) MAPTKDM4EKMT2ATSHRALDH1A1
SCHEMBL18650747 0.76 MAPT (0.58) MAPTKDM4EGLAKMT2APGR
SCHEMBL28627795 0.75 KDM4E (0.63) MAPTKDM4EGLAKMT2ATSHR
SCHEMBL19894095 0.74 MAPT (0.61) MAPTKDM4EGLAKMT2AALDH1A1
SCHEMBL2242408 0.73 MAPT (0.46) MAPTKDM4EGLAKMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1645430-B1 METHOD FOR PRODUCING MATERIAL CONTAINING SENSITIZER DISPERSED THEREIN FOR HEAT-SENSITIVE RECORDING MATERIAL SANKO CO LTD (JP) 2011-11-30 EP disclosed
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition EMORY UNIVERSITY (US) 2011-11-10 US disclosed
EP-2328578-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION Emory University (US) 2011-06-08 EP disclosed
WO-2010030582-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION EMORY UNIVERSITY (US) 2010-03-18 WO disclosed
US-20090233246-A1 METHOD FOR PRODUCING MATERIAL CONTAINING SENSITIZER DISPERSED THEREIN FOR THERMAL RECORDING ARTICLE AND THERMAL RECORDING ARTICLE ODA SHIGERU 2009-09-17 US disclosed
US-7557065-B2 Method for producing material containing sensitizer dispersed therein for thermal recording article and a thermal recording article SANKO CO., LTD. (JP) 2009-07-07 US disclosed
US-20060252645-A1 Method for producing material containing sensitizer dispersed therein for thermal recording article an thermal recording article SANKO CO., LTD. (JP) 2006-11-09 US disclosed
EP-1645430-A1 METHOD FOR PRODUCING MATERIAL CONTAINING SENSITIZER DISPERSED THEREIN FOR THERMAL RECORDING ARTICLE AND THERMAL RECORDING ARTICLE Sanko Co., Ltd. (JP) 2006-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition NOS1, NOS2, TBCA MAPT 28/4885KDM4E 4136/4885GLA 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.